6-methoxy-2-pyridin-3-yl-1H-indole | 519158-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-methoxy-2-pyridin-3-yl-1H-indole
• CAS: 519158-36-2
• 化学式: C₁₄H₁₂N₂O
• 分子量: 224.262
• InChiKey: XPRSIKUVZZNDTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-methoxy-2-pyridin-3-yl-1H-indole 、 N,N-二甲基甲酰胺 在 三氯氧磷 作用下， 生成 6-methoxy-2-(pyridin-3-yl)-1H-indole-3-carbaldehyde
  参考文献：
  名称：

  BICYCLIC COMPOUND

  摘要：

  公开号：

  EP1447400B1
• 作为产物：
  描述：

  5-methoxy-2-[(pyridin-3-yl)ethynyl]aniline 在 potassium tert-butylate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成 6-methoxy-2-pyridin-3-yl-1H-indole
  参考文献：
  名称：

  BICYCLIC COMPOUND

  摘要：

  公开号：

  EP1447400B1

文献信息

• INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  申请人：Tatani Kazuya

  公开号：US20130317065A1

  公开（公告）日：2013-11-28

  The present invention provides a compound represented by the general formula (I) of the present invention, which has EP 1 receptor antagonism: wherein A represents a benzene ring, a pyridine ring, or the like; Y 1 represents a C 1-6 alkylene group or the like; Y 2 represents a single bond or the like; Z represents —C(═O)—NHSO 2 R 6 , an acidic 5-membered hetero ring group, or the like; R 1 represents a hydrogen atom or the like; R 2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group, or the like; R 4 represents a hydrogen atom, a halogen atom, or the like; R 5 represents a hydrogen atom or the like; and R 6 represents a C 1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种化合物，其表示为本发明的一般式（I），具有EP1受体拮抗作用：其中A代表苯环、吡啶环或类似物；Y1代表C1-6烷基或类似物；Y2代表单键或类似物；Z代表—C(═O)—NHSO2R6、酸性5-成员杂环基团或类似物；R1代表氢原子或类似物；R2代表苯基、5-成员芳香杂环基团或类似物；R3代表卤原子、C1-6烷氧基或类似物；R4代表氢原子、卤原子或类似物；R5代表氢原子或类似物；R6代表C1-6烷基或类似物，或其药学上可接受的盐。此外，本发明的化合物（I）可用作治疗或预防LUTS的药剂，特别是OABs的各种症状。
• Bicyclic compound
  申请人：Miyoshi Shiro

  公开号：US20050020602A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R 2 represents NHSO 2 R 3 , etc., provided that R 3 represents C 1-6 alkyl, etc. R 5 represents hydrogen, etc. R 6 and R 7 may be the same or different and each independently represents hydrogen, etc. X represents oxygen, etc. Y represents oxygen, etc. Z 1 to Z 6 each represents carbon, etc. n is an integer of 0 to 6 and ast1 indicates that the carbon atom is asymmetric, and *2, in the case where R 5 is not hydrogen, indicates that the carbon atom is asymmetric or a salt of the compound.

  化合物的通式为I：I，其中R1代表氢等，R2代表NHSO2R3等，但R3代表C1-6烷基等，R5代表氢等，R6和R7可以相同也可以不同，且各自独立地代表氢等，X代表氧等，Y代表氧等，Z1至Z6各自代表碳等，n为0至6的整数，ast1表示碳原子是不对称的，*2表示当R5不是氢时，碳原子是不对称的或化合物的盐。
• Indole compounds as B3 androceptor agonist
  申请人：Miyoshi Shiro

  公开号：US20080076815A1

  公开（公告）日：2008-03-27

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式(I)的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是(C1-C6)烷基或类似物；R5是氢原子或类似物；R6和R7可以相同或不同，且各自独立地是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1至Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST
  申请人：Miyoshi Shiro

  公开号：US20080015242A1

  公开（公告）日：2008-01-17

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式（I）的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是（C1-C6）烷基或类似物；R5是氢原子或类似物；R6和R7可以相同也可以不同，分别是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1到Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• Indole derivative and pharmacologically acceptable salt thereof
  申请人：Tatani Kazuya

  公开号：US08815903B2

  公开（公告）日：2014-08-26

  The present invention provides a compound represented by the general formula (I) of the present invention, which has EP1 receptor antagonism: wherein A represents a benzene ring, a pyridine ring, or the like; Y1 represents a C1-6 alkylene group or the like; Y2 represents a single bond or the like; Z represents —C(═O)—NHSO2R6, an acidic 5-membered hetero ring group, or the like; R1 represents a hydrogen atom or the like; R2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like; R3 represents a halogen atom, a C1-6 alkoxy group, or the like; R4 represents a hydrogen atom, a halogen atom, or the like; R5 represents a hydrogen atom or the like; and R6 represents a C1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种由本发明的通式（I）所表示的化合物，其具有EP1受体拮抗作用：其中A代表苯环，吡啶环或类似物；Y1代表C1-6烷基或类似物；Y2代表单键或类似物；Z代表-C（═O）-NHSO2R6，酸性5-成员杂环基团或类似物；R1代表氢原子或类似物；R2代表苯基，5-成员芳香杂环基团或类似物；R3代表卤原子，C1-6烷氧基或类似物；R4代表氢原子，卤原子或类似物；R5代表氢原子或类似物；R6代表C1-6烷基或类似物]，或其药学上可接受的盐。此外，本发明的化合物（I）可用作治疗或预防下尿路症状（LUTS），特别是OAB的各种症状的药剂。